October 2, 2025 — Leads & Copy — Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced today the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock. This includes the underwriters’ full exercise of their option to purchase an additional 975,000 shares, priced at $10.00 each.
All shares were offered by Enanta, with gross proceeds totaling $74.75 million before deductions. Enanta plans to allocate the net proceeds, along with existing funds, to support clinical trials, research and development, working capital, and other corporate needs.
J.P. Morgan, Jefferies, and Evercore ISI served as the joint book-running managers for the offering. The securities were offered under a shelf registration statement on Form S-3 filed with the SEC on November 22, 2023, effective February 8, 2024.
Copies of the final prospectus supplement are available on the SEC’s website and from J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C.
Contact:
[No contact information provided in the press release]
Source: Enanta Pharmaceuticals, Inc.
